Podbit · The Prof G Pod with Scott Galloway
Lilly bet on GLP-1s in 2018 when nobody else was — obesity was considered a non-market. Combined with a 5-year cut in R&D cycle time and a singular Midwestern execution culture, those three factors compounded into a trillion-dollar market cap and fivefold stock return.
Where this was said
At 31:10 · chapter starts 25:25
Scott Galloway asks for a plain-English explainer on peptides — a word now everywhere in wellness culture. Ricks obliges with a short biochemistry lesson: a peptide is simply a chain of amino acids, a foundational term in biology, and the fact that online marketing has made it sound exotic says more about modern commerce than science. His critique of the unregulated peptide market is pointed: these are 'unstudied medicines,' substances sold without clinical trials, safety data, or any third-party verification of what's actually in them. Some mimic growth hormone — which is also pro-tumor growth, Ricks notes drily. But the more revealing part of his answer is the sociological diagnosis: the peptide boom is a symptom of a genuinely broken consumer healthcare experience. No prices, long waits, condescension, information asymmetry — all of it has driven people to take agency online, armed with N-of-1 anecdotes and biochemistry they can't verify. 'That's not science,' Ricks says, but he acknowledges the underlying frustration is legitimate. The healthcare system has earned some of the distrust now being directed at it.
The booming online peptide market is selling substances without clinical trials, safety data, or FDA approval. Lilly's CEO calls them 'unstudied medicines' — and connects the craze to justified rage at a broken healthcare system that leaves patients feeling financially and informationally powerless.
Spend 80% of your landing page design time above the fold. The hero section is the only thing most visitors will ever truly read, so it needs to deliver your full message instantly.
Avnish grew his solo business to $25,000 per month in just 15 months without spending a dollar on ads. His entire growth engine was built on community posts in Reddit and Facebook groups.
One well-crafted post in the right community took Avnish from single thousands of users to tens of thousands. This wasn't luck — it was a repeatable part of his 5-step playbook.
Most founders chase paid ads and influencer deals, but Avnish's growth came entirely from knowing where his users already gathered online. Dominating Reddit and Facebook groups — for free — was his entire strategy.
The dominant mobile monetization flow is simple: free download, onboarding, then a hard paywall that blocks all features until the user pays or starts a trial. It's unskippable by design — and that's exactly the point.
Switching PuffCount to a hard paywall and requiring a free trial before any feature access sent conversion rates soaring to 20–25%. One structural change to the payment flow — no new features, no new users — transformed the business.
Vasco is so confident in YouTube that he'll personally PayPal $500 to anyone who posts for 45 days and doesn't make $5,000. This isn't hype — it's a distillation of his own experience growing an AI app to $70K/month using nothing but daily videos.
Vasco's AI app went from zero to $70,000 a month in just two years. The entire growth engine was YouTube — one video a day, nothing fancy, no expensive tools. Most of his users came directly from the channel.
People buy from people they know, like, and trust. YouTube is the only platform that builds all three at scale — and Vasco's $1M business is the proof of concept.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.